|
KR20040105740A
(ko)
|
2002-02-25 |
2004-12-16 |
엘란 파마슈티칼스, 인크. |
염증 치료제의 투여 방법
|
|
EP1545611B1
(en)
*
|
2002-09-06 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
CN103040732B
(zh)
|
2003-02-10 |
2015-04-01 |
伊兰药品公司 |
免疫球蛋白制剂及其制备方法
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
*
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
PL1729810T3
(pl)
*
|
2004-04-02 |
2019-02-28 |
Swedish Orphan Biovitrum Ab (Publ) |
Sposoby agregacji IL-1ra
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CA2587597A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
|
EP1865986B1
(en)
*
|
2005-03-08 |
2016-02-17 |
Pfizer Products Inc. |
Anti-ctla-4 antibody compositions
|
|
AU2006247039B2
(en)
|
2005-05-19 |
2011-03-03 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
AU2006291005A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-CD3 antibody formulations
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
SI3219328T1
(sl)
*
|
2005-12-29 |
2020-10-30 |
Janssen Biotech, Inc. |
Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
|
|
HUE066795T2
(hu)
|
2006-03-15 |
2024-09-28 |
Alexion Pharma Inc |
Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
WO2008039761A2
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
CA2665567C
(en)
*
|
2006-10-06 |
2012-07-03 |
Amgen Inc. |
Stable formulations
|
|
US7705132B2
(en)
|
2006-10-20 |
2010-04-27 |
Amgen Inc. |
Stable polypeptide formulations
|
|
JP5419709B2
(ja)
*
|
2007-01-09 |
2014-02-19 |
ワイス・エルエルシー |
抗ｉｌ−１３抗体製剤およびその使用
|
|
CN101674734A
(zh)
*
|
2007-02-12 |
2010-03-17 |
拉萨德·布杰贝尔 |
不含防腐剂的无菌三氯蔗糖溶液
|
|
CA2690382A1
(en)
|
2007-06-14 |
2008-12-24 |
Biogen Idec Ma Inc. |
Antibody formulations
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
CN106443002A
(zh)
*
|
2007-10-22 |
2017-02-22 |
贝克顿·迪金森公司 |
评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
PT2271382E
(pt)
|
2008-04-15 |
2013-05-07 |
Grifols Therapeutics Inc |
Ultrafiltração em dois andares/diafiltração
|
|
WO2010027766A1
(en)
|
2008-08-27 |
2010-03-11 |
Schering Corporation |
Lyophilized formulatons of engineered anti-il-23p19 antibodies
|
|
TWI445716B
(zh)
*
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Ｐｃｓｋ９拮抗劑類
|
|
MX2011005672A
(es)
*
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
EP2381929B1
(en)
*
|
2008-12-29 |
2015-07-08 |
Samyang Biopharmaceuticals Corporation |
Pharmaceutical composition of lyophilized formulation and preparation method of the same
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
MX2011010971A
(es)
*
|
2009-04-17 |
2012-01-19 |
Biogen Idec Inc |
Composiciones y metodos para tratar leucemia mielogena aguda.
|
|
US20100278822A1
(en)
*
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
PT2477603E
(pt)
*
|
2009-09-17 |
2016-06-16 |
Baxalta Inc |
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
|
|
JP2013507131A
(ja)
*
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
SI3409289T1
(sl)
*
|
2010-02-26 |
2020-12-31 |
Novo Nordisk A/S |
Stabilni sestavki, ki vsebujejo protitelo
|
|
ES2912934T3
(es)
|
2010-04-16 |
2022-05-30 |
Biogen Ma Inc |
Anticuerpos anti VLA-4
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
EP3626263A1
(en)
|
2010-06-04 |
2020-03-25 |
Wyeth LLC |
Vaccine formulations
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PL2616090T3
(pl)
|
2010-09-17 |
2023-12-18 |
Takeda Pharmaceutical Company Limited |
Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3722808B1
(en)
|
2010-10-25 |
2024-09-11 |
Biogen MA Inc. |
Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
|
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
WO2012135408A1
(en)
|
2011-03-31 |
2012-10-04 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
PH12013502442A1
(en)
*
|
2011-05-26 |
2018-03-21 |
Glaxo Smithkline Biologicals Sa |
Inactivated dengue virus vaccine
|
|
EA026226B1
(ru)
*
|
2011-07-01 |
2017-03-31 |
Байоджен Айдек Ма Инк. |
Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
KR102063028B1
(ko)
*
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ａｎｇ2 항체를 함유하는 안정화된 제형
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
JP6265970B2
(ja)
*
|
2012-03-26 |
2018-01-24 |
サノフイ |
安定なＩｇＧ４に基づく結合剤の製剤
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
*
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2819217T3
(es)
|
2013-09-08 |
2021-04-15 |
Kodiak Sciences Inc |
Conjugados de polímeros iónicos dipolares y factor VIII
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
SI3071237T1
(sl)
|
2013-11-21 |
2024-11-29 |
Genmab A/S |
Liofilizirana formulacija konjugata protitelo-zdravilo
|
|
US9932591B2
(en)
|
2013-12-18 |
2018-04-03 |
University Of Delaware |
Reduction of lipase activity in product formulations
|
|
WO2015200905A2
(en)
|
2014-06-28 |
2015-12-30 |
Oligasis, Llc |
Dual pdgf/vegf antagonists
|
|
EP3207128B1
(en)
|
2014-10-17 |
2022-07-27 |
Kodiak Sciences Inc. |
Butyrylcholinesterase zwitterionic polymer conjugates
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
US20210322549A1
(en)
*
|
2015-07-17 |
2021-10-21 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Natalizumab
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
IL290457B2
(en)
|
2015-12-30 |
2025-02-01 |
Kodiak Sciences Inc |
Antibodies and their conjugates
|
|
JP2019505520A
(ja)
|
2016-01-13 |
2019-02-28 |
ゲンマブ エー／エス |
抗体およびその薬物コンジュゲートの製剤
|
|
CN107063940B
(zh)
|
2016-02-10 |
2019-10-18 |
贝克顿迪金森法国公司 |
用于评价基于蛋白质的制剂的稳定性的方法
|
|
BR112019001806A2
(pt)
|
2016-07-29 |
2019-05-07 |
Momenta Pharmaceuticals, Inc. |
anticorpos para fcrn e métodos de uso dos mesmos
|
|
EP3541413A2
(en)
|
2016-11-21 |
2019-09-25 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
EP3459527B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
|
EP3720483B1
(en)
|
2017-12-06 |
2025-11-19 |
Merck Sharp & Dohme LLC |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
MA51032A
(fr)
*
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
CA3092588A1
(en)
|
2018-03-02 |
2019-09-06 |
Kodiak Sciences Inc. |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
JP7516250B2
(ja)
|
2018-03-05 |
2024-07-16 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
WO2019173767A1
(en)
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
CN112292146A
(zh)
|
2018-04-10 |
2021-01-29 |
雷迪博士实验室有限公司 |
治疗性抗体的稳定的制剂
|
|
US12024561B2
(en)
*
|
2018-04-10 |
2024-07-02 |
Dr. Reddy's Laboratories Limited |
Stable antibody formulation
|
|
SG11202009874QA
(en)
*
|
2018-04-10 |
2020-11-27 |
Dr Reddys Laboratories Ltd |
Antibody formulation
|
|
JP7460608B2
(ja)
|
2018-05-07 |
2024-04-02 |
ジェンマブ エー／エス |
抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
|
|
CN112867394B9
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
JP7486437B2
(ja)
|
2018-06-08 |
2024-05-17 |
アルジェニクス ビーブイ |
免疫性血小板減少症を治療する組成物及び方法
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
US12171764B2
(en)
|
2018-06-20 |
2024-12-24 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
|
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
CN112566652A
(zh)
*
|
2018-06-25 |
2021-03-26 |
Jcr制药股份有限公司 |
含有蛋白的水性液体制剂
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
|
EP3897705A2
(en)
|
2018-12-19 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
JP7555929B2
(ja)
*
|
2018-12-24 |
2024-09-25 |
遠大賽威信生命科学（南京）有限公司 |
Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
|
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
|
BR112021024632A2
(pt)
*
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
|
|
MX2021015213A
(es)
*
|
2019-06-11 |
2022-01-18 |
Macrogenics Inc |
Formulaciones farmaceuticas de diacuerpos biespecificos y uso de las mismas.
|
|
CA3148826A1
(en)
*
|
2019-08-01 |
2021-02-04 |
Janssen Biotech, Inc. |
Fcrn antibodies and methods of use thereof
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CN114786724A
(zh)
*
|
2019-12-16 |
2022-07-22 |
尼普洛株式会社 |
防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
US20230151102A1
(en)
*
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
JP2023512991A
(ja)
*
|
2020-01-29 |
2023-03-30 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体生成からの宿主細胞リパーゼの分離方法
|
|
CA3183927A1
(en)
|
2020-05-21 |
2021-11-25 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
US20230340131A1
(en)
*
|
2020-11-12 |
2023-10-26 |
Dr. Reddy’S Laboratories Limited |
Stable aqueous high concentration formulation of integrin antibody
|
|
WO2023174925A1
(en)
|
2022-03-14 |
2023-09-21 |
Novimmune Sa |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
KR20250037789A
(ko)
|
2022-06-15 |
2025-03-18 |
아르젠엑스 비브이 |
Fcrn/항원-결합 분자 및 사용 방법
|
|
EP4720125A1
(en)
|
2023-05-30 |
2026-04-08 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|
|
EP4762093A1
(en)
|
2023-08-14 |
2026-06-24 |
Paragon Therapeutics, Inc. |
Alpha 4 beta 7 integrin binding proteins and methods of use
|